Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
Recruiting
Observational Study
Metastatic NSCLC - Non-Small Cell Lung Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Necmettin Erbakan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm.
Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histological and staging diagnosis of metastatic non-small cell lung cancer
* ECOG performance score between 0 and 2
* No contraindications for nivolumab
Exclusion Criteria:
* Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy
* Those …
Contacts